Day: August 23, 2023

Oslo, Norway, 23rd of August 2023 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the second quarter and first half of 2023. Revenue in the second quarter ended at MNOK 107 compared to MNOK 69 in Q2 2022. Increased volume from the new production line compared to the same quarter last year has resulted in more volumes available for sale. Revenue for first half of 2023 ended at MNOK 208 compared to MNOK 102 YTD last year, a 103% increase. Second quarter EBITDA ended at MNOK 19.6 (MNOK 4.7). EBITDA positively affected by increased sales volume, competitive electricity prices and a stronger EUR vs NOK, partly offset by a stronger USD vs NOK. In addition, economies of scale are materializing as the MEP volume ramps up. EBITDA for first half of 2023 ended at MNOK 33.7 compared to negative MNOK 13.5 YTD...

Ghent , Aug. 23, 2023 (GLOBE NEWSWIRE) — Press release – regulated informationStrategic partnership with Syngenta to collaborate on the research and development and commercialisation of a new bio-insecticide Field trials with Evoca™* continue to demonstrate competitive performance in fruits and vegetables; trials now ongoing for additional crops such as blueberries and hemp Update on regulatory approval process for Evoca Successful CFO succession with Douglas Minder in function since July 1st Private placement of new shares for €7 million at market value Cash and cash equivalents amounted to €32 million end of June 2023 Management to host a conference call and live webcast today at 15:00 CEST / 14:00 BST / 09:00 EDT, details belowBiotalys (Euronext – BTLS), an Agricultural Technology (AgTech) company developing...

Vow ASA (OSE: VOW) reported continued high revenues of NOK 449 million in the first six months of 2023, representing a growth of 12 per cent year-over-year. EBITDA before non-recurring items came in at NOK 29.6 million for the period and corresponding to a margin of 6.6 per cent. EBITDA reflects good performance in cruise and heat treatment, and the costs of building pipeline in Industrial Solutions. “We are consistently delivering good results in our well-established business. We are strategically building capacity and intensifying our bidding for projects in new industry verticals. The demand for our offerings is evident, and we possess the relevance and capability to meet these needs. As a result, we remain steadfast in our commitment to seize these opportunities, even if it temporarily impacts our EBITDA,” said Henrik Badin, CEO of...

  HIGH REVENUE AND EARNINGS IMPROVEMENT Lerøy posted a 17% year-on-year increase in revenue for Q2 2023. Operating EBIT was NOK 950 million, up slightly from NOK 927 million in Q2 2022. Operating EBIT/kg through the value chain was NOK 28.7, against NOK 25.2 in the same period of last year. The second quarter has been impacted by price inflation on seafood products and a challenging situation in the Farming segment in the second half of 2022, which has resulted in low harvest weights and a low harvest volume in the first half of this year. The Group’s downstream activities showed a significant improvement from the same period of 2022 and, despite lower quotas this year, Wild Catch posted satisfactory results for Q2. Henning Beltestad explains that the long production time for salmon means it takes time for improved performance to be reflected...

(Bergen, 23 August 2023) Mowi recorded all-time high revenue of 1 365 million euros in the second quarter of 2023, compared with 1 232 million euros in the corresponding quarter of 2022. Operational profit was also strong at 300 million euros in the quarter. Mowi delivered yet another record-breaking set of results in the second quarter, driven by strong operational performance in all business areas in addition to good prices. “Strong volumes, good salmon prices and, most importantly, excellent operational performance by my 11 500 colleagues across the world, resulted in a new record-breaking quarter for Mowi. I am very pleased to see continuous improvement over time throughout the value chain,” Mowi CEO Ivan Vindheim said. Mowi harvested 107 500 tonnes of salmon in the quarter, above guidance of 104 500 tonnes. Full-year harvest guidance...

OSLO, Norway, Aug. 23, 2023 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the second quarter and first half of 2023. The financial report can be accessed in the Investors section of the Company’s website: https://nykode.com/investors/financial-reports-and-presentations. The Company will host a webcast presentation at 3 p.m. CET / 9 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website and on the following link: https://event.webcasts.com/starthere.jsp?ei=1630447&tp_key=80c6064a80. About Nykode TherapeuticsNykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the...